Abstract:Purpose/Objective(s) Voice changes are common in head and neck cancer (HNC) survivors who undergo radiation therapy (RT). Most studies have assessed changes with validated patient reported outcomes measures (PROMS). There is a need to combine PROMS with patient voice recordings. The purpose of this study was to characterize voice changes using a standardized protocol and describe primary aberrant features using expert listeners. Materials/Methods This study enrolled long-term survivors (>2 years) of locally advanced (T3+ or N+) HNC who received ≥60 Gy at a single academic center. Patients completed a standardized protocol of several vocal tasks. Recordings included a single reading of the first 4 sentences of the Rainbow Passage and sustained /a/ and /i/ edited to the first 3 seconds of each phoneme. Nine blinded speech language pathologists with voice specialization rated dysphonia using the CAPE-V visual analog scale. Scores ranged 1-100 with higher scores indicating greater dysphonia. Mean scores across the 9 listeners were calculated and severity of dysphonia was classified for this study as normal [0-12), mild [12-20), mild-moderate [20-30), moderate [30-45), moderate-severe [45-60), severe [60-85), and severe-profound [85-100]. A 10% repeat assessment was used for intra-rater reliability. Cronbach's alpha was calculated to assess inter-rater consistency. Primary aberrant features were roughness, breathiness, tremor, spasm, strain, and asthenia. Changes in voice resonance were indicated with a binary yes/no. Results Two hundred one patients were enrolled with 198 recordings available for analysis. Median time from completion of RT was 5.6 years (range 1.7-28.9 years). Most common primary disease sites were oropharynx (51%), larynx (12%), and oral cavity (11%). Seventy-two percent of patients were male. Surgery and systemic therapy were included in 58% and 63% of treatment courses, respectively. Mean CAPE-V score for all patients was 31.9 (IQR 19.9 – 38.1). Dysphonia was classified as normal in 6.6%, mild in 18.7%, mild-moderate in 28.8%, moderate in 27.2%, moderate-severe in 11.1%, severe in 7.1%, and severe-profound in 0.5% of patients. In the validation cohort, the median percent difference in CAPE-V scores between initial and repeat assessments was 5.5% (IQR 2.0-12.5%). Cronbach's alpha was 0.95. In 64.6% of patients, at least 50% of listeners reported voice roughness as the primary aberrant feature, while breathiness, tremor, spasm, strain, and asthenia were reported in 2%, 0.5%, 0%, 7.6%, and 1.5%, respectively. Resonance changes were noted in 20.7% of patients by over half of listeners. Conclusion Dysphonia was present in many long term HNC survivors following RT with 45% having at least moderate dysphonia. Voice roughness was the most common primary aberrant feature with many bearing changes in resonance. Further understanding of clinical factors predictive of vocal changes and treatment factors mediating changes is needed to develop strategies to mitigate this late toxicity.

Longitudinal Patient-Reported Voice Quality in Early-Stage Glottic Cancer

Healing process following laser cordectomy of early glottis carcinoma from endoscopic view.

Long-Term Laryngeal Function and Quality of Life Following Treatment of Early Glottic Cancer: A Meta-Analysis

Spectro-acoustic voice parameters in transoral laser microsurgery vs exclusive radiotherapy for early-stage glottic carcinoma: A systematic review and meta-analysis

Evaluation of lasersurgery and radiotherapy as treatment modalities in early stage laryngeal carcinoma: tumour outcome and quality of voice

The Voice Quality after Laser Surgery Versus Radiotherapy of T1a Glottic Carcinoma: Systematic Review and Meta-Analysis

Characterizing Voice Changes and Primary Aberrant Features in Survivors of Locally Advanced Head and Neck Cancer Treated with Radiation Therapy

Life quality improvement in hoarse patients with early glottic cancer after transoral laser microsurgery

Long-term swallowing outcomes of radiotherapy and transoral laser microsurgery for T1 glottic cancer treatment

A Retrospective Study Based on Our 10-Year Experience

Preoperative and Postoperative Voice in Tis-T1 Glottic Cancer Treated by Endoscopic Cordectomy: An Additional Issue for Patient Counseling

Voice quality after open partial horizontal laryngectomy vs. total laryngectomy with voice prosthesis: a comparative study

Factors Impacting Provider Treatment Decision‐Making in Early Glottic Cancer

Voice Outcome in Patients Treated With Endoscopic Laryngopharyngeal Surgery for Superficial Hypopharyngeal Cancer

Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis

Oncological Outcomes of Transoral Laser Microsurgery for Early Stage Glottic Cancer with Involvement of the Anterior Commissure

Voice-Related Quality of Life in Post-Laryngectomy Rehabilitation: Tracheoesophageal Fistula’s Wellness

Quality of Life in Recurrent Respiratory Papillomatosis Patients after Vocal Fold Surgery: An In-Depth Exploration

Comparison of Current Surgical and Non-Surgical Treatment Strategies for Early and Locally Advanced Stage Glottic Laryngeal Cancer and Their Outcome

Oncologic outcomes of transoral laser microsurgery versus open partial laryngectomies in the management of early stage glottic carcinoma

A Comparative Assessment of Voice after Laser Surgery Versus Radiotherapy of T1a Glottic Carcinoma:A Meta-Analysis